Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMR69CG)

Drug Name

XEN-402 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Osteoarthritis	FA00-FA05	Phase 2	[1]
Pain	MG30-MG3Z	Phase 2	[2]
Vasodilatation of extremities	EG00	Phase 2	[3]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.7 (SCN9A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PF-05089771	DMD74BJ	Chronic pain	MG30	Phase 2	[5]
BIIB074	DMLV1ET	Bipolar disorder	6A60	Phase 2	[6]
DSP-2230	DM0WTMD	Neuropathic pain	8E43.0	Phase 1	[6]
BIIB095	DMUC6EP	Pain	MG30-MG3Z	Phase 1	[6]
GDC0310	DMUNFEP	Chronic pain	MG30	Phase 1	[7]
DSP-3905	DMYHU24	Neuropathic pain	8E43.0	Phase 1	[6]
PF-05241328	DM2NTBL	Pain	MG30-MG3Z	Phase 1	[8]
DWJ-208	DMQKDJZ	Cancer related pain	MG30	Phase 1	[6]
RG7893	DM1R4MQ	Pain	MG30-MG3Z	Phase 1	[9]
PF-05186462	DMUF6W9	Pain	MG30-MG3Z	Phase 1	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated sodium channel alpha Nav1.7 (SCN9A)	TT4G2JS	SCN9A_HUMAN	Inhibitor	[4]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02068599) A Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 Ointment) in Participants With Primary Osteoarthritis (OA) Affecting a Single Knee. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT01195636) A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN). U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain. 2012 Jan;153(1):80-5.
5	Primary erythromelalgia: a review. Orphanet J Rare Dis. 2015 Sep 30;10:127.
6	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	Recent progress in sodium channel modulators for pain. Bioorg Med Chem Lett. 2014 Aug 15;24(16):3690-9.
9	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041740)
10	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026875)